Effects of ATH434, a Clinical-Phase Small Molecule with Moderate Affinity for Iron, in a Parkinson’s Disease Model in Macaques
Objective: (1) Determine whether oral ATH434 improves motor performance in a non-human primate hemiparkinasonian model when administered after symptom onset. (2) Relate observations to changes…Oropharyngeal Adverse Events in Parkinson’s Patients with Motor Fluctuations Treated with Apomorphine Sublingual Film
Objective: This post-hoc analysis of Study CTH-301 assessed the occurrence of oropharyngeal treatment-emergent adverse events (TEAEs) in patients with Parkinson’s disease included in this study.…Pharmacokinetics of Levodopa after Subcutaneous bolus delivery of foslevodopa/foscarbidopa
Objective: To characterize the pharmacokinetics (PK) of levodopa (LD) after bolus delivery of foslevodopa/foscarbidopa Background: Foslevodopa/foscarbidopa is a soluble formulation of LD/CD prodrugs delivered as…Longitudinal Changes in Quality of Life After Subthalamic Nucleus Deep Brain Stimulation in Parkinson’s Disease
Objective: To clarify longitudinal changes in QOL in PD after STN-DBS. Background: While it is well known that motor complications are dramatically improved after subthalamic…Antipsychotic Prescriptions Among Nursing Home Residents with Parkinson’s Disease in the End-of-Life Period
Objective: To determine whether antipsychotic prescriptions differ between community-dwelling and nursing home residents with PD in the last 6 months of life. Background: Most antipsychotics…Deciphering the Role of Auranofin-Loaded Nanoparticles Against Rotenone Model of Parkinson’s Disease: Via GSK-3β/ Nrf2/HO-1 Signaling Pathways
Objective: To investigate the neuroprotective effect of AUF-loaded nanoparticles in animal models of Parkinson's disease by modulating GSK-3β/ Nrf2/HO-1 Signaling Pathways. Background: Parkinson's disease (PD) is…Genetic signatures stratify PwP into three subgroups with differing responses in two disease-modifying Phase 3 trials and indicate multiple disease biology pathways to Parkinson’s Disease
Objective: To evaluate if 3 newfound genetic subgroups represent differing aspects of disease biology in PD by determining if subgroup participants have differing responses to…Safety and Tolerability of Bemdaneprocel in People With Parkinson’s Disease: Results up to 24 Months From a Phase 1 Study
Objective: To report the safety and tolerability of bemdaneprocel in participants with Parkinson’s disease (PD) up to 24 months post transplantation. Background: Bemdaneprocel is an…Resting-State Network Alterations in Patients with Isolated REM Sleep Behavior Disorder and their Association with Clinical Symptoms
Objective: To characterize brain functional connectivity (FC) in patients with isolated REM sleep behavior disorder (iRBD) and its associations with clinical features. Background: Patients with…Decrease in Walking Ability with Increased Functional Connectivity between Multiple Brain Areas in Parkinson’s Disease
Objective: To compare the functional connectivity of PFC, PMC, and PSC regions during walking between individuals with Parkinson's disease and healthy controls. Background: Gait disturbances…
- « Previous Page
- 1
- …
- 75
- 76
- 77
- 78
- 79
- …
- 338
- Next Page »